KTTA Pasithea Therapeutics Corp.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KTTA
—
—
What changed
Recent filings, trades and moves- Nov 12 Reports earnings
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 5
- List Date
- 2021-09-15
- CIK
- 0001841330
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.21)
- Headquarters
- Miami Beach, FL
- Homepage
- https://www.pasithea.com
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -27.93% | 9.40% | -18.63% | -23.55% | -27.65% | -17.67% |
| Feb | -- | -25.55% | -32.38% | 21.21% | -45.28% | 4.31% | -15.54% |
| Mar | -- | 26.21% | -24.70% | -10.82% | 18.18% | -8.87% | 0.00% |
| Apr | -- | -6.98% | -12.52% | -4.28% | 33.87% | -6.63% | 0.69% |
| May | -- | -26.71% | 5.45% | -23.42% | -36.18% | -14.95% | -19.16% |
| Jun | -- | 4.12% | 39.96% | -11.37% | -22.44% | -27.92% | -3.53% |
| Jul | -- | 16.00% | 28.62% | 0.00% | -1.29% | -20.02% | 4.66% |
| Aug | -- | 0.88% | 0.92% | -9.16% | 15.75% | 28.53% | 7.38% |
| Sep | -14.61% | 9.57% | -21.37% | 11.75% | -18.57% | -12.43% | -7.61% |
| Oct | -1.39% | -16.15% | -26.32% | -19.77% | 5.74% | -24.31% | -13.70% |
| Nov | 40.47% | -8.31% | -6.86% | -18.68% | 80.17% | 47.36%* | 22.36% |
| Dec | -46.36% | -36.47% | 15.99% | 6.06% | 11.21% | -- | -9.91% |
| Total | -36.55% | -69.90% | -41.57% | -59.86% | -35.42% | -60.47% | -50.63% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.44
SMA 50: $0.48
SMA 200: $0.62
Current: $0.54
EMA 12: $0.48
EMA 26: $0.46
MACD: 0.0160 | Signal: 0.0210
BEARISH
ADX (14): 27.37
TREND
+DI: 32.12
−DI: 12.60
Momentum Oscillators
RSI (14): 61.43
NEUTRAL
Stoch %K: 80.33
Stoch %D: 80.90
Williams %R: -25.89
Volume & Volatility
BB Upper: $0.57
BB Lower: $0.31
NEUTRAL
OBV: 786,601,697
Vol SMA 20: 1,583,720
Vol ROC: -62.53%
ATR: $0.06
True Range: $0.08
HV 20: 164.5%
HV 30: 136.5%
HV 60: 107.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
LLM Stock Analysis Report: KTTA
Executive Summary
Overall assessment: BEARISH with confidence level 6/10 Key drivers: High volatility, negative news sentiment, technical sell signals Primary risks: Overbought momentum, declining prices Investment thesis: Short-term bearish trend, potential for further price decline before a possible reversal. Recent news sentiment impact: Negative headlines from Thea Foundation and Pasithea Therapeutics' product launch announcement have weighed on the stock.
Technical Analysis
Trend Direction: Bearish short-term (1-4 weeks), neutral medium-term (1-3 months), bearish long-term (3-12 months)
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- Support: $0.43 (Bollinger Bands lower band)
- Resistance: $0.46 (SMA 20)
Momentum Signals:
- RSI interpretation: Overbought (55.01) with a potential sell signal
- MACD signal: Bearish momentum with a negative histogram (-0.02)
- Bollinger Bands position: Overbought and potentially reversing
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: Decreasing volume, indicating low institutional interest
- On-Balance Volume (OBV): Negative OBV, confirming bearish momentum
- Volume Rate of Change: High negative volume rate, suggesting further price decline
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Pasithea Therapeutics' positive PAS-004 tablet pharmacokinetic data and closing of $60 million public offering have been overshadowed by Thea Foundation's notice to disregard.
- Mixed sentiment with some positive and negative headlines.
Sentiment Assessment: Aggregate news sentiment: NEGATIVE (4/5)
Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- No significant catalysts announced in the near term
- Pasithea Therapeutics' Phase 1/1b trial data may provide a potential bullish catalyst
Market Narrative: News aligns with or contradicts technical signals: Negative news sentiment and technical sell signals support the bearish thesis.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta >1.2 = high risk, <0.8 = defensive): 1.32 (high risk)
Volatility Regime: Current vs historical volatility levels: High volatility, higher than average
Options Market Signals: IV rank: N/A (no options data available), put/call ratios: No significant signals, unusual activity: None
Downside Protection: Support levels and risk management considerations:
- Potential support at $0.43 (Bollinger Bands lower band)
- Risk management: Stop-loss level at $0.45 to limit potential losses
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: Weak performance in the healthcare sector
Institutional Activity: Volume patterns suggesting institutional interest:
- Decreasing volume, indicating low institutional interest
- No significant buying or selling pressure observed
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Low correlation coefficient (<0.5) indicates a lack of relationship between KTTA and the broader market
Relative Valuation: Position within trading range:
- Stock is near the lower end of its recent trading range
- Potential for further price decline before a possible reversal
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- $0.43 (Bollinger Bands lower band)
- $0.46 (SMA 20)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Break below $0.43 to confirm bearish trend
- Break above $0.46 to indicate a potential reversal
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- No significant catalysts announced in the near term
Risk Management: Stop-loss levels and position sizing considerations:
- Stop-loss level at $0.45 to limit potential losses
- Position sizing: 10% of portfolio allocated for KTTA due to high risk and volatility
Generated
News
All KTTA news →
KTTA Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.4127
Alpha: 57.37%
Correlation: 0.1191
R-Squared: 1.4%
Stock Volatility: 163.1%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own KTTA
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $34K | #3071 of 3138 | -29.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KTTA Institutional Ownership (13F)
Filings for 2026-06-30 · 2 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
KTTA Board & Officers
As of SEC filings through Jun 22, 2026Directors 4
- Emer Leahy · since Sep 14, 2021
- Lawrence Steinman · since Sep 14, 2021
- Simon Dumesnil · since Sep 14, 2021
- Tiago Marques · since Sep 14, 2021
Officers 3
- Tiago Marques · Chief Executive Officer · since Sep 14, 2021
- Daniel H Schneiderman · Chief Financial Officer · listed since Oct 2022
- Kartik Krishnan · Chief Medical Officer · since May 1, 2026
10% owners 1
- Coastlands Capital LP (entity) · since Apr 9, 2026
Changes in the last 10 years (24)
| May 1, 2026 | Kartik Krishnan became Chief Medical Officer |
| Apr 9, 2026 | Coastlands Capital LP became a 10% owner |
| Jul 3, 2023 | Graeme Martin Currie became Chief Development Officer |
| Oct 22, 2022 | Tiger Lily Capital, LLC became a 10% owner |
| Oct 22, 2022 | Paul B Manning became a 10% owner |
| Oct 22, 2022 | PD Joint Holdings, LLC Series 2016-A became a 10% owner |
| Oct 22, 2022 | Bradford Manning became a 10% owner |
| Oct 12, 2022 | Daniel H Schneiderman listed as Chief Financial Officer (previously Interim Chief Accting Officer) in SEC filings |
| Sep 14, 2022 | The company announced the departure of Yassine Bendiabdallah from the board in an SEC filing |
| Sep 14, 2022 | The company announced the departure of Alfred J Novak from the board in an SEC filing |
| Sep 14, 2022 | Alfred J Novak became a director |
| Aug 12, 2022 | Daniel H Schneiderman became Interim Chief Accting Officer |
| Jun 7, 2022 | The company announced the departure of Stanley Gloss as Chief Financial Officer in an SEC filing |
| Sep 14, 2021 | Yassine Bendiabdallah became a director |
| Sep 14, 2021 | Yassine Bendiabdallah became Chief Operating Officer |
| Sep 14, 2021 | Tiago Marques became a director |
| Sep 14, 2021 | Tiago Marques became Chief Executive Officer |
| Sep 14, 2021 | Stanley Gloss became Chief Financial Officer |
| Sep 14, 2021 | Simon Dumesnil became a director |
| Sep 14, 2021 | Lawrence Steinman became a director |
| Sep 14, 2021 | Israel Maxx Abramowitz became a 10% owner |
| Sep 14, 2021 | Eric Lazer became a 10% owner |
| Sep 14, 2021 | Emer Leahy became a director |
| Sep 14, 2021 | Dean Lazer became a 10% owner |
Not reported recently (9)
- Graeme Martin Currie · Last reported as Chief Development Officer in an SEC filing dated Apr 5, 2024
- Bradford Manning · Last reported as a 10% owner in an SEC filing dated Feb 14, 2023
- Paul B Manning · Last reported as a 10% owner in an SEC filing dated Feb 14, 2023
- Tiger Lily Capital, LLC · Last reported as a 10% owner in an SEC filing dated Feb 14, 2023
- PD Joint Holdings, LLC Series 2016-A · Last reported as a 10% owner in an SEC filing dated Feb 14, 2023
- Yassine Bendiabdallah · Last reported as Chief Operating Officer in an SEC filing dated Sep 14, 2021
- Israel Maxx Abramowitz · Last reported as a 10% owner in an SEC filing dated Sep 14, 2021
- Eric Lazer · Last reported as a 10% owner in an SEC filing dated Sep 14, 2021
- Dean Lazer · Last reported as a 10% owner in an SEC filing dated Sep 14, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
KTTA Proposed Insider Sales (Form 144)
Latest: 2025-05-14
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-05-14 | Tiago Reis Marques | Officer, Director | 960 | $798 | 2025-05-12 | DEGIRO | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-09-16
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-14 | 0001213900-26-090146 | EDGAR |
ETF Holders
2 ETFs hold KTTA
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
KTTA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences Inc | $16.7B | 25.1 | +38.0% | +20.1% | 26 |
| DFTX Definium Therapeutics, Inc. Common Share | $4.5B | — | — | +130.1% | 30 |
| ATAI AtaiBeckley Inc. Common Stock | $2.7B | — | +811.8% | +89.9% | — |
| CMPS COMPASS Pathways Plc American Depository | $1.2B | — | — | +40.2% | 28 |
| ANRO Alto Neuroscience Inc. | $987M | — | — | +67.6% | 41 |
| HELP Helus Pharma Inc. Common Stock | $658M | — | — | +21.2% | 100 |
| RLMD Relmada Therapeutics, Inc. Common Stock | $416M | — | — | −5.3% | 21 |
| NRXP NRX Pharmaceuticals, Inc. Common Stock | $103M | — | — | −9.2% | 37 |
| KTTA Pasithea Therapeutics Corp. Common Stock | $19M | — | — | −54.4% | — |
| Peer median | $1.1B | 25.1 | +424.9% | +30.7% | 30 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.